Drug Trial Radar · NCT02966171
A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies
Last checked: Nov 19, 2026Latest source record: Nov 21, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
14
Actual
Start
Jan 2017
Primary completion
Aug 23, 2018
Study completion Aug 23, 2018
Sponsor
- Lead sponsor
- Hutchison Medipharma LimitedIndustry
- Sponsor type
- Industry
- First posted
- Nov 17, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-time-in-human, phase I, open-label, dose-escalation study of HMPL-453 in patients with advanced or metastatic solid malignancies who have failed or are intolerable to standard therapies or for whom no standard therapies exist. There are preliminary two stages in this study: a dose-escalation stage (stage 1) and a dose-expansion stage (stage 2). We will decide whether to conduct stage 2 or not one month after the last patient included in stage 1.
Conditions
- Solid Tumor
Interventions
HMPL-453Drug
oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of DLTs by the NCI CTCAE v4.03Time frame: Cycle 1 (DLT assessment window, 28 days) of multiple dosing peroid
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
St Vincent's Cancer Services
Sydney, New South Wales, Australia
Chris O'Brien Lifehouse
Sydney, New South Wales, Australia
Peninsula and Southeast Oncology
Frankston, Victoria, Australia
Monash Medical Centre
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.